Konstantinos Alataris Net Worth

The estimated Net Worth of Konstantinos Alataris is at least $143 mil dollars as of 20 March 2017. Konstantinos Alataris owns over 127,389 units of Zosano Pharma Corp stock worth over $142,676 and over the last 9 years Konstantinos sold ZSAN stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Konstantinos Alataris ZSAN stock SEC Form 4 insiders trading

Konstantinos has made over 2 trades of the Zosano Pharma Corp stock since 2016, according to the Form 4 filled with the SEC. Most recently Konstantinos exercised 127,389 units of ZSAN stock worth $184,714 on 20 March 2017.

The largest trade Konstantinos's ever made was exercising 127,389 units of Zosano Pharma Corp stock on 20 March 2017 worth over $184,714. On average, Konstantinos trades about 50,956 units every 43 days since 2015. As of 20 March 2017 Konstantinos still owns at least 254,778 units of Zosano Pharma Corp stock.

You can see the complete history of Konstantinos Alataris stock trades at the bottom of the page.

What's Konstantinos Alataris's mailing address?

Konstantinos's mailing address filed with the SEC is 34790 Ardentech Ct, Fremont, CA 94555, USA.

Insiders trading at Zosano Pharma Corp

Over the last 10 years, insiders at Zosano Pharma Corp have traded over $5,506,679 worth of Zosano Pharma Corp stock and bought 790,627 units worth $1,835,090 . The most active insiders traders include M James Barrett, Enterprise Associates 12, L..., eSteve Elms. On average, Zosano Pharma Corp executives and independent directors trade stock every 60 days with the average trade being worth of $44,258. The most recent stock trade was executed by Christine Matthews on 6 June 2022, trading 82 units of ZSAN stock currently worth $58.

What does Zosano Pharma Corp do?

Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is Qtrypta™ (M207), which is a proprietary formulation of zolmitriptan designed to be delivered via its transdermal microneedle system technology, as an acute treatment for migraine.

Complete history of Konstantinos Alataris stock trades at Zosano Pharma Corp

Zosano Pharma Corp executives and stock owners

Zosano Pharma Corp executives and other stock owners filed with the SEC include:

• Steven Lo,
  Sr. VP of Operations, Pres, CEO & Director
• Dr. Donald J. Kellerman,
  VP of Clinical Devel. & Medical Affairs
• Kleanthis Xanthopoulos,
  Independent Director
• Kenneth Greathouse,
  Independent Director
• Steven Elms,
  Independent Director
• Joseph Hagan,
  Director
• Linda Grais,
  Director
• Thorsten von Stein,
  Chief Medical Officer
• Eric Scharin,
  Vice President - Technical Operations
• Dushyant Pathak,
  Senior Vice President - Business Development
• Christine Matthews,
  Chief Financial Officer, Principal Financial Officer
• Steven Lo,
  Chief Executive Officer, Director
• John Walker,
  Chairman of the Board
• Kristina Warga,
  VP & Corp. Controller
• Lu Liu,
  VP of Technical Operations
• Jeffrey L. Quillen,
  Sec.
• Hayley Lewis,
  Sr. VP of Operations
• Christine Matthews,
  Chief Financial Officer
• Capital Iv, Lp Aisling Capi...,
  
• Winnie Wing Kei Tso,
  Chief Financial Officer
• Georgia Erbez,
  Interim CFO
• Konstantinos Alataris,
  President
• M James Barrett,
  Director
• Enterprise Associates 12, L...,
  
• Troy Edward Wilson,
  Director
• Enterprise Associates 12, L...,
  
• Kathy M. Mc Gee,
  Director
• Capital Management, Llc Kaz...,
  
• Gregory David Kitchener,
  Chief Financial Officer
• Elaine Yang,
  Director
• Enterprise Associates 12, L...,
  
• Realty Trust Inc Bio Med Re...,
  
• Laxmi Peri,
  Sr. Vice President, Operations
• Hayley Lewis,
  See Remarks
• Steve Elms,
  Director
• Donald J Kellerman,
  VP, Clinical Dev & Med Affairs